To establish a Biotechnology Management Office in the Department of Defense and to provide support for the research and development of bioindustrial manufacturing processes, and for other purposes.
- Sponsor
- Rep. Neguse, Joe [D-CO-2]
- Committees
- Armed Services Committee (primary)
- Last action
- Dec 11, 2025
Bottom line
This bill aims to enhance the DoD's biotechnology and bioindustrial manufacturing capabilities by creating a dedicated oversight office and clarifying funding authorities for infrastructure development.
What it actually does
This bill establishes a Biotechnology Management Office within the Department of Defense (DoD) to centralize and accelerate the development, acquisition, and sustainment of biotechnology capabilities. It also amends existing law to explicitly allow Department of Defense research, development, test, and evaluation (RDT&E) funds to be used for bioindustrial manufacturing processes, including design and construction activities.
Proponents argue
Supporters would argue that establishing a dedicated office and clarifying funding for bioindustrial manufacturing is crucial for national security, ensuring the DoD remains at the forefront of technological innovation and maintains a competitive edge against adversaries. They contend it streamlines processes, fosters public-private partnerships, and addresses critical supply chain resilience needs.
Opponents contend
Critics might argue that creating a new office could lead to bureaucratic bloat or overlap with existing DoD functions, potentially diverting resources without clear added value. Concerns could also be raised about the sunset provision, which might limit long-term strategic planning, or the broad funding language allowing RDT&E funds for construction, which could be seen as expanding the scope of such funds without sufficient oversight.
The bill is very short and straightforward, making it highly accessible for a reader to understand its core provisions quickly.
Section 1(a), (b), (c)
Establishment of Biotechnology Management Office
This section mandates the Secretary of Defense to designate a senior official with biotechnology experience within 90 days of enactment. This official will head the new Biotechnology Management Office, which must be chartered and established within 120 days under the Deputy Secretary of Defense. The office is responsible for developing a long-term roadmap, updating policies, coordinating efforts across government and industry, streamlining processes, conducting global analyses, fostering public-private partnerships, and identifying workforce gaps related to biotechnology.
Supporters argue
Supporters argue that a dedicated, high-level office is essential to provide strategic direction and coordination for the DoD's diverse biotechnology efforts, preventing fragmentation and accelerating the adoption of critical technologies for national security.
Critics contend
Critics might contend that the DoD already has various offices and initiatives related to emerging technologies, and establishing a new, separate office could lead to bureaucratic redundancy or competition for resources rather than genuine streamlining.
Tradeoffs
The tension lies between the need for focused strategic leadership in biotechnology and the risk of creating another layer of bureaucracy within an already complex defense apparatus.
Section 1(d)
Termination of Biotechnology Management Office
This subsection stipulates that the Biotechnology Management Office established under Section 1 shall terminate on September 30, 2030. This sets a fixed lifespan for the office, implying a period for initial establishment and operation, after which its continued existence would require new legislative action.
Section 2
Funding for Bioindustrial Manufacturing Processes
This section amends the James M. Inhofe National Defense Authorization Act for Fiscal Year 2023 by adding a new subsection (d) to Section 215. This new subsection explicitly states that funds authorized for Department of Defense research, development, test, and evaluation (RDT&E) may be used to carry out bioindustrial manufacturing activities, including design and construction. This clarifies and potentially expands the permissible uses of RDT&E funds for these purposes.